Trials / Unknown
UnknownNCT04226989
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- He Huang · Academic / Other
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.
Detailed description
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-cell hematological malignancy: B-ALL and B-NHL, the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 2 groups of patients will be enrolled, 36 in each group. Primary objective is to explore the safety, main consideration is dose-related safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CT-RD06 | CT-RD06 cell injection by intravenous infusion |
Timeline
- Start date
- 2020-02-05
- Primary completion
- 2022-02-05
- Completion
- 2024-05-31
- First posted
- 2020-01-13
- Last updated
- 2020-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04226989. Inclusion in this directory is not an endorsement.